首页 > 产品中心 > 抗体 > 药物对照抗体

Research Grade Eldelumab (HY524016)

价格:
规格:
  • 100ug
  • 1mg
数量:
  • 概述
  • 图片
  • 参考文献
  • 产品说明书
概述
货号HY524016
品牌abinScience
种属反应性Human
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主Human
同种型IgG1-kappa
表达系统Mammalian Cells
种属Human
克隆类型Monoclonal
靶标Gamma-IP10, C-X-C motif chemokine 10, INP10, 10 kDa interferon gamma-induced protein, Small-inducible cytokine B10, SCYB10, IP-10, CXCL10
内毒素水平Please contact with the lab for this information.
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
Accession号P02778
状态Liquid
保存溶液0.01M PBS, pH 7.4.
稳定性和存储Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
别名BMS-936557, MDX-1100, 946414-98-8
背景Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis.
• The human gene encoding SCYB9B, a putative novel CXC chemokine, maps to human chromosome 4q21 like the closely related genes for MIG (SCYB9) and INP10 (SCYB10)., PMID:9730616
NoteFor research use only. Not suitable for clinical or therapeutic use.
图片
  • Bioactivity

    Detects CXCL10/IP-10 in indirect ELISAs.

参考文献

相关产品推荐